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1. Introduction 
Proper vascular network structure is essential for normal tissue function. The vasculature 
provides oxygen, nutrients and immune cells, as well as removes tissue waste and by-
products. (Jain 2003) In tissue engineering and regenerative medicine, the existence of 
functional blood vessels is critical to the survival of the newly generated tissue. Current 
strategies for promoting new blood vessel formation, or neovascularization, have mostly 
focused on angiogenesis, which is the formation of new capillaries from pre-existing vessels 
by sprouting of endothelial cells (ECs). (Carmeliet 2003) Another mechanism of 
neovascularization, vasculogenesis, which is the in situ assembly of endothelial progenitors 
into capillaries, has also been explored as a method for stimulating new vessel formation. 
Genes or proteins of angiogenic factors have been delivered systematically or directly to a 
target tissue to promote neovascularization via either angiogenesis or vasculogenesis. For 
example, proteins from the vascular endothelial growth factor (VEGF) and fibroblast growth 
factor (FGF) families delivered by various methods have been investigated extensively for 
enhancing neovascularization. (Brey et al., 2005; Brey & McIntire, 2008)   
While the delivery of angiogenic factors has been successful in promoting new capillary 
formation, the structure of the newly formed vessels is often non-ideal. The vessels can be 
immature, with small diameters and lack of some essential cellular and extracellular 
components required for proper function. Immature vascular structure may result in poor 
blood perfusion and possibly vessel regression upon a decrease in the vascular stimulus. 
(Benjamin et al., 1999) In addition, the formation of small capillaries alone is not likely to be 
sufficient for vascularization of large, complex tissues, which are often needed for tissue 
engineering. Therefore, the goal of neovascularization in engineered tissue should be 
focused not only on the initial assembly of capillaries via angiogenesis or vasculogenesis, 
but also the expansion and stabilization of new vessels, which means the formation of 
mature, long-lasting vessels with dimensions that meet the requirement of high conductance 
blood flow. (Carmeliet & Conway, 2001) In this chapter, we will discuss current status in the 
generation of stable, long-lasting vascular networks in tissue engineering and regenerative 
medicine, identifying recent advances and limitations yet to be overcome. 
2. Angiogenesis stabilization: basic mechanisms 
The process of angiogenesis includes four stages: (a) initiation, in which a certain angiogenic 
stimulus increases vessel permeability and protein leakage; (b) progression, characterized 
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by the production of proteolytic enzymes that degrade the basement membrane (BM) lining 
endothelial cells (ECs) and surrounding extracellular matrix (ECM) to allow EC invasion 
and migration; (c) differentiation, which involves the assembly of ECs into a network with a 
luminal structure; and (d) stabilization and maturation, where mural cells (pericytes and 
vascular smooth muscle cells) are recruited and ECs deposit new BM. (Bussolino et al., 1997) 
It is important to note that the MCs may be recruited after initial network function or 
simultaneous with vessel assembly. (Brey et al., 2004) Numerous cellular and molecular 
factors are involved in the regulation of this process. Failure in this regulation could result 
in excessive vessel generation or premature regression, which is seen in many pathological 
conditions. In the following sections we will describe the basic components of the vessel and 
their role in vessel stability. 
2.1 Cells 
The walls of stable blood vessels are composed of two distinct cell types: ECs and mural 
cells (MCs). (Figure 1) While ECs form the inner lining of vascular tubes, MCs associate with 
and coat the outside of the endothelial tube. (Gaengel et al., 2008) In the case of capillaries 
the MCs, or pericytes, are intermittently present on the surface. For larger vessels the MCs, 
or vascular smooth muscle cells (VSMCs), coat the entire vessel surface often in multiple 
layers. Interactions between the ECs and MCs play a critical role in the regulation of 
vascular formation, stabilization, remodeling, and function. Abnormal interactions between 
the two cell types are implicated in a number of pathological conditions, including tumor 
angiogenesis, diabetic microangiopathy, ectopic tissue calcification, and stroke and 
dementia syndrome. (Armulik et al., 2005; Carmeliet 2003)  
 
 
Fig. 1. Process of blood vessel stabilization. Endothelial cells (EC) in immature vessels 
secrete signals that stimulate the migration and proliferation of mural cells (MC). ECs also 
secrete a thin layer of matrix, known as the basement membrane (BM) that lines the vessels 
Junctional structures, including adherent junctions and tight junctions, are present between 
ECs and provide the endothelium with integrity, mechanical strength and tightness, and a 
barrier to molecular transport. (Carmeliet 2003) During vascular sprouting, junctions are 
partially disorganized to allow cell migration and proliferation, and to increase vessel 
permeability. During vessel stabilization, junctional integrity is re-established and 
permeability is tightly controlled. (Dejana, 2004) As vessels sprout and migrate, they will 
www.intechopen.com
 
Formation of Stable Vascular Networks in Engineered Tissues 
 
479 
form branches. These sprouts then inosculate with other vessels to form complex networks. 
Typically, a high vessel density is formed in response to the initial vascular stimuli. This 
vasculature must be remodeled for tissue-specific transport and function. Apoptosis of ECs 
are involved at this later stage to remove excessive vessels. (Darland & D'Amore, 2001) 
However, excessive apoptosis may result in premature vessel regression. Growth factors, 
which are essential for angiogenesis, not only stimulate EC proliferation and migration 
but also inhibit EC apoptosis. (Dimmeler & Zeiher, 2000) Thus, the prevention of EC 
apoptosis may improve the survival and durability of blood vessels formed in engineered 
tissues. 
MCs are commonly subdivided into VSMCs, which are associated with arteries and veins 
forming multiple concentric layers; and pericytes, which are associated with small diameter 
capillaries. (Gaengel et al., 2009) Intermediate-size vessels, arterioles and venules, have MCs 
with properties between those of typical VSMCs and pericytes. Since VSMCs and 
pericytes share some common cellular markers, such as α-smooth muscle actin (α-SMA) 
and desmin, they are believed to represent phenotypic variants of the same lineage, and 
may function as progenitors for each other depending on external stimuli. (Gerhardt & 
Betsholtz, 2003)    
The presence of MCs on the surface of ECs plays a critical role in vessel stability. 
Intercellular adhesion between MCs and ECs is mediated by integrin ┙4┚1, which is 
expressed by proliferating ECs, and its ligand VCAM-1, which is expressed by proliferating 
MCs. (Garmy-Susini et al., 2005) Studies have shown that the association of MCs to the 
newly formed endothelial plexus stabilizes the vasculature, while the disruption of EC-MC 
associations results in excessive regression of vasculature. (Benjamin et al., 1998) Co-culture 
of EC with SMC in a 3D in vitro model results in a mature, quiescent EC phenotype with 
increased number junctional structures and increased resistance to apoptosis. (Korff et al., 
2001) However, the presence of MCs in the microvasculature does not always guarantee 
vessel stability. Vessels with extensive MC can still regress following loss of neovascular 
stimuli. (Brey et al., 2004) Therefore, some additional signals, such as ECM and soluble 
growth factors, are also required for vessel stabilization.  
2.2 Extracellular components 
Extracellular matrices (ECM), including BM (primarily collagen IV and various laminin 
isoforms) and interstitial matrices (typically collagen I, elastin and fibronectin but depends 
on the particularly tissue), play important roles in angiogenesis. (Francis et al., 2008) Firstly, 
the ECM scaffold provides mechanical support for ECs to form channels, preventing vessels 
from collapsing. In addition, EC adhesion to ECM regulates EC proliferation, migration, 
and survival, mediated by different signaling pathways. (Davis & Senger, 2005) And 
finally, the deposition of ECM, particularly BM, which occurs after MC recruitment 
stabilizes the vessel by decreasing permeability and preventing vessel regression. 
(Stratman et al., 2009)    
The ECM is dynamically regulated during angiogenesis. In the initiation of angiogenesis, 
ECM is degraded by proteinases, such as matrix metalloproteinases (MMPs). The 
degradation of ECM not only allows EC migration and proliferation, but also releases 
soluble growth factors trapped in the matrix. (Ghajar et al., 2008) After lumen formation, 
MCs are recruited to EC tubes and induce the deposition of new BM as well as the secretion 
of tissue inhibitor of metalloproteinases (TIMPs), which inhibit MMPs proteolysis. (Stratman 
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et al., 2009) Dysregulation of ECM, such as glycation of collagen due to diabetes and aging, 
can slow ECM vessel assembly. (Francis-Sedlak et al., 2010) 
2.3 Signaling pathways 
The formation of stable vasculature is tightly regulated by the spatial and temporal kinetics 
of numerous signaling pathways. A stable, operational vascular network results from a 
balance between signals that favor angiogenesis and vascular stabilization, and those that 
promote vascular regression. (Bussolino et al., 1997) Signaling pathways affect vascular 
stabilization presumably by regulating proliferation and apoptosis of ECs and MCs, as well 
as the deposition and degradation of ECM. (Jain 2003) In this section, we will discuss some 
of the signaling pathways and their roles in vascular stabilization. 
2.3.1 Platelet derived growth factor (PDGF) family 
The PDGF family is composed of disulfide-bonded homodimers of four subunits, PDGF-
A, PDGF-B, PDGF-C and PDGF-D, as well as the heterodimer PDGF-AB. PDGF isoforms 
exert their biological effects through the activation of two tyrosine kinase receptors, 
PDGFR-┙ and PDGF-┚, which are present on MCs and messenchymal cells. (Hellberg et 
al., 2010)  
Specifically, PDGF-BB, secreted by proliferating ECs during angiogenic sprouting, 
stimulates the migration and proliferation of MCs, which express PDGFR-┚. In addition, 
PDGF-BB induces the differentiation of messenchymal cells toward a MC lineage.(Hirschi et 
al., 1999) Genetic knockout of pdgf-b or pdgfr-β in mice results in MC deficiency, vascular 
leakage and embryonic lethality (Hellstrom et al., 1999; Lindahl et al., 1997) The more 
recently described PDGF-C and PDGF-D isoforms are also involved in vessel maturation 
and stabilization. PDGF-C drives the recruitment and differentiation of MCs resulting in 
improved BM integrity and a more mature, stable vascular wall with a lower permeability. 
(di Tomaso et al., 2009) PDGF-D induces macrophage recruitment and vessel stabilization by 
improving the SMC coating of angiogenic blood vessels and decreases their permeability. 
(Uutela et al., 2004) 
2.3.2 Angiopoietins  
The angiopoietin (Ang) family consists of Ang-1, Ang-2, Ang-3 and Ang-4. The 
angiopoietins are ligands for the Ties, a family of receptors that are expressed within the 
vascular endothelium. (Yancopoulos et al., 2000) Ang-1 is predominantly expressed by MCs, 
suggesting a paracrine mode of action; whereas Ang-2 is mostly expressed by ECs, 
suggesting an autocrine function, although expression in MCs has also been reported. 
(Gaengel et al., 2009) Ang-3 and Ang-4 are less well understood at this time.  
Ang-1 stabilizes nascent vessels and make them leak-resistant, presumably by facilitating 
interactions between ECs and MCs. Genetic deletion of Ang-1 or its receptor Tie2 in mice 
resulted in defects in vessel remodeling with poor association of ECs with BM, and failure to 
recruit MCs. (Sato et al., 1995; Suri et al., 1996) Transgenic overexpression of Ang-1 in mice 
lead to a significant increase in vessel diameter and increased resistance to vessel leakage. 
The resistance is presumably due to the ability of Ang-1 to maximize interactions between 
ECs, MCs and BM. (Thurston et al., 1999, 2000) Ang-2, on the other hand, acts as an 
antagonist of Ang-1, destabilizes vessels and contributes to vessel regression. Transgenic 
overexpression of Ang-2 disrupts blood vessel formation in the mouse embryo, resulting in 
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similar effects to Ang-1 or Tie 2 knockouts. (Maisonpierre et al., 1997) Thus, angiopoietins 
positively or negatively regulate vessel stabilization, however, the detailed mechanism of 
the signaling pathways are not yet well-described.   
2.3.3 Sphingosine-1-Phosphate (S1P) 
S1P is a bioactive lipid mediator that is primarily secreted by platelets. It activates a 
family of G-protein coupled receptors (S1P1 to 5), formerly known as endothelial 
differentiation gene (Edg)-receptors. (Gaengel et al., 2009) Mice deficient in S1P have 
severe vascular defects resulting in embryonic lethality, with incomplete coverage of 
MCs. Mice deficient in S1P1, its receptor, also showed severe defect in vascular 
maturation, suggesting the role of S1P/S1P1 signaling pathway in promoting vascular 
stabilization. (Mizugishi et al., 2005) Moreover, knockout of the EC-specific S1P1 in mice 
embryos resulted in a similar phenotype as obtained for the S1P1 full knockout, 
suggesting that S1P1 functions mainly through ECs instead of other cell types. (Allende et 
al., 2003) It was found that S1P/S1P1 signaling pathway promotes vascular stabilization 
by activation of N-Cadherin, which is a cell adhesion molecule connecting ECs and MCs. 
(Paik et al., 2004) 
2.3.4 Transforming growth factor-β (TGF-β) 
TGF- β, a growth factor family with three different isoforms TGF-β1, TGF-β2 and TGF-β3, is 
expressed by a number of cell types, including ECs and MCs. Depending on its receptor 
TGF-β mediates distinct signaling pathways. TGF-β can be both pro- and anti-angiogenic. 
(Pepper 1997) The major receptors for TGF-β in regulating vascular stabilization include 
activin receptor-like kinase (Alk)-1, Alk-5, and endoglin. (Gaengel et al., 2009)  
Activation of Alk-1 triggers EC migration, proliferation, and inhibits vessel maturation and 
MC differentiation; whereas activation of Alk-5 instead mediates inhibition of EC migration, 
reduced proliferation, increased vessel maturation and MC differentiation, suggesting that 
TGF-β regulates vessel maturation and stabilization via a balance between Alk-1 and Alk-5. 
(Goumans et al., 2002) The determination of which signaling pathway TGF-β activates 
appears to depend on its concentration. At low doses, TGF-β promotes EC proliferation by 
activating TGF-β /Alk-1 pathway; while at high doses, Alk-5 is activated instead. (van den 
Driesche et al., 2003) Endoglin, a TGF-β co-receptor expressed specifically in ECs, modulates 
Alk-1 and Alk-5 mediated pathways, possibly by favoring the TGF-β/Alk-1 pathway. 
(Letamendia et al., 1998)  
2.3.5 Vascular endothelial growth factor (VEGF) family 
VEGF is a family of angiogenic growth factors expressed by a variety of cells, including 
keratinocytes, macrophages, mast cells, vSMCS, and ECs. Members of the VEGF family 
include VEGF-A, VEGF-B, VEGF-C, VEGF-D and placental growth factor (PlGF). VEGF is a 
major mitogen for ECs, mediated via VEGF tyrosine kinase receptors (VEGFRs) expressed 
on ECs. (Bussolino et al., 1997; Yancopoulos et al., 2000) It has been shown that VEGF plays a 
central role in neovascularization by stimulating ECs proliferation, migration and increasing 
vascular permeability in a number of physiological and pathological processes. (Nor et al., 
1999)  
However, the role of VEGF in regulating vascular stabilization can be both positive and 
negative, depending on its spatial and temporal kinetics. On the one hand, VEGF enhances 
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EC survival and protects EC from apoptosis by up-regulating the expression of Bcl-2 (B-cell 
lymphoma 2), an apoptosis regulator protein. (Nor et al., 1999) Withdrawal of VEGF prior to 
stabilization and remodeling may result in excessive vessel regression by EC apoptosis. 
(Benjamin et al., 1999; Jain, et al., 1998) On the other hand, VEGF is also considered as a 
negative regulator for vessel maturation by disrupting VSMC function and pericyte 
coverage of nascent vascular sprouts, leading to vessel destabilization. (Greenberg et 
al.,2008). The overexpression of VEGF results in leaky, immature and unstable vessels, 
which contribute to a number of pathological conditions, such as tumors, diabetic 
retinopathy, and age-related macular degeneration (AMD). Therefore, the dosage of 
VEGF must be tightly regulated in a spatial, temporal and quantitative manner in 
therapeutic applications to avoid abnormal or aberrant vascular structure. (Yancopoulos 
et al., 2000) 
2.3.6 Ephrins and notch 
Ephrins and Notch are two signals that are generally involved in the differentiation of many 
cell types. In angiogenesis, the two signaling pathways are involved in the determination of 
arterio-venous vessel fate. (Jain 2003) Thus, the ephrins and Notch signaling pathways are 
considered novel targets for therapeutic angiogenesis. (Sullivan & Bicknell, 2003; Cristofaro 
& Emanueli, 2009) The ephrin ligands and Eph receptors are both transmembrane molecules 
expressed on ECs and other cell types.(Yancopoulos et al., 2000; Cristofaro & Emanueli, 
2009) The ligand ephrin-B2 is expressed specifically in the arterial endothelium, while the 
receptor EphB4 expresses in the venous endothelium. The distribution suggest a role in 
defining boundaries between arterial and venous domains. (Adam et al., 1999; Wang et al., 
1999). Notch is a family of transmembrane protein receptors that bind to ligands 
Delta/Serrate. The Notch pathway, in angiogenesis, is also required for arterial-venous 
differentiation. (Sullivan & Bicknell, 2003; Gaengel et al., 2009) Activation of Notch signaling 
leads to repression of venous cell fate in EC, while ablation of Notch function resulted in 
defects in blood vessel formation similar to those associated with improper arterial-venous 
specification. (Lawson et al., 2001; Liu et al., 2003) 
2.3.7 Others 
There are a number of other signaling pathways involved in the formation of stable 
vasculature. For example, brain derived neurotrophic factor (BDNF) is a neurotrophin for 
neuron survival and differentiation. It is also an EC survival factor involved in 
intramyocardial vessel stabilization, by activation of trk B receptors expressed on cardiac 
microvascular ECs.(Donovan et al., 2000) Monocyte chemotatic protein-1 (MCP-1) is a small 
cytokine best known for its ability to recruit monocytes after injury. However, recent studies 
have shown that MCP-1 improves vessel stabilization during angiogenesis by promoting 
MC recruitment and inducing VSMC proliferation. (Aplin et al., 2010; Selzman et al., 2002) 
Nitric oxide (NO), a multifunctional gaseous molecule that regulates various physiological 
functions is also involved in vascular stabilization. An in vivo tissue-engineered blood vessel 
model revealed that NO mediates EC-MC interaction and induces MC recruitment, vessel 
branching, and longitudinal extension and subsequent stabilization of the vessels. 
(Kashiwagi et al., 2005) A summary of the of numerous signalling pathways is provided in 
Table 1, with ligand/receptor pairs, cells that express these molecules, and their roles in 
vessel maturation and stabilization.  
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Ligand (Cells) Receptor (Cells) Roles in vessel stabilization 
Ang-1 (MCs) Tie2  
(ECs, MSCs) 
Stabilizes vessels by mediating EC-MC and EC-
ECM adhesion; Induces production of factors 





Destabilizes vessels  by binding to Tie2 to 
attenuate the effect of Ang-1. 




Trk-B (neurons; ECs; 
MCs ) 
Promotes intramyocardial arteries and capillaries 




Notch (ECs) Determines arterial-venous fate of ECs by 
repressing venous fate in arterial ECs. 
Ephrin-B2 
(Arterial ECs)  
Eph-B4 (Venous ECs)
 
Determines arterial and venous EC 
specialization. 
HB-EGF (ECs) ErbB1, ErbB2 (MCs) Promotes MCs proliferation and protects from 





Induces SMC migration, mediating angiopoietins 





Mediates spontaneous and Ang-1 induced MC 
recruitment. 
PDGF-BB (ECs) PDGFR-┚ (MCs; 
MSCs) 
Promotes MC migration and proliferation; 
Induces MSCs differentiation to MCs. 
S1P (Platelets) S1P1  
(MCs) 
Activates adhesion molecule connecting ECs and 




Promotes EC migration and proliferation; 




Induces MC differentiation and ECM production; 
Inhibits EC migration and proliferation. 
TGF-┚  
(ECs; MCs) 
Endoglin (ECs) Modulates Alk-1 and Alk-5 mediated pathway 




VEGFRs (ECs)  Enhances EC survival by inducing Bcl-2 
expression; Inhibits MC association and increases 
vessel permeability. 
Table 1. Signaling Pathways Regulating Vessel Stabilization 
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Many of the signaling pathways mentioned above work in a coordinated fashion to regulate 
vessel stabilization. For example, MCP-1 was found to be one of the many cytokines 
released during angiopoietin induced MC recruitment.(Aplin et al., 2010) Other cytokines 
involved in angiopoietin function include EC-derived heparin binding-epidermal growth 
factor (HB-EGF) (Iivanainen et al., 2009; Stratman et al., 2010) and hepatocyte growth factor 
(HGF) (Kobayashi et al., 2006). PDGF-BB was found to promote MC proliferation partially 
by inducing the release of fibroblast growth factor-2 (FGF-2), which in turn transactivates 
FGFR-1. (Millette et al., 2006) PDGF-B stimulation also induces an acute production of TGF-
β, which in turn, negatively regulates Ang-1 expression induced by the PDGF-B stimulation. 
(Nishishita & Lin, 2004) Thus, a complex interaction of multiple signaling pathways is 
required to maintain vascular homeostasis and vascular stabilization. 
3. Tissue engineering strategies 
Extensive attention has been given to tissue engineering for its potential to restore, maintain 
or improve tissue functions. (Langer & Vacanti, 1993) However, the clinical application of 
engineered tissues requires the ability to form extensive, stable microvascular networks 
within engineered tissues. (Brey & McIntire, 2008) While strategies for neovascularization, 
including angiogenesis, vasculogenesis and arteriogenesis, have been extensively reviewed 
elsewhere (Brey et al., 2005; Ennett & Mooney, 2002; Sneider et al., 2009), increased attention 
is being given to the later stage of neovascularization, which is the maturation and 
stabilization of newly formed vessels. Different tissue engineering strategies, including 
protein delivery, gene therapy and cell therapy (Table 2) have been developed and tested in 
both in vitro and in vivo models.   
 
 Advantages Disadvantages 
Protein 
Delivery 
Better dose control than gene therapies; 
Temporal control over release can be 
achieved with certain delivery systems. 
Expensive to produce and isolate 
proteins;  




Long-term active growth factor 
expression; 
Delivery restricted to area of modified 
cells 
Safety issues based on delivery 
methods; 
Difficult to control the level and 
duration of gene expression; 
Limited transfection efficiency. 
Cell 
Therapy 
Introducing cell population that is 
sensitive to stimuli unlike many cells in 
the disease/damaged tissue  
Cells can stimulate neovascularization by 
incorporation into new vessels or release 
of soluble factors 
Costly and time consuming for cell 
isolation and expansion; 
Limited cell sources for autologous 
transplantation; 
Immunosuppresive medications 
needed for allogeneic or exnogeneic 
transplantation. 
Table 2. Advantages and Disadvantages of General Strategies for Promoting Stable 
Neovascularization in Engineered Tissues 
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3.1 Protein delivery 
3.1.1 Single factor delivery 
The formation of a stable vascular network during normal healing involves a complex 
spatial and temporal regulation of a large number of angiogenic stimulators and inhibitors. 
(Jain, 2003) While it may seem logical that all of these factors would be required in order to 
generate vessels in engineered tissues, researchers have attempted to initiate the entire 
process through the delivery of a single factor. Members of the VEGF and FGF families were 
some of the first identified angiogenic growth factors and have been used in clinical trials 
for the treatment of limb ischemia. (Cao et al., 2005) However, the short term delivery of 
basic FGF (FGF-2) or VEGF may result in immature vessels, stable for only a short time prior 
to regression. (Dellian et al., 1996) Based on these issues others have chosen to use factors 
with a known role in angiogenesis stabilization. For example, PDGF-BB, Ang-1, HGF, and 
ephrin-B2 are some of the factors  currently under investigation in animal and in vitro 
models. (Brey & McIntire, 2008) 
It is possible that the short lifetime and immaturity exhibited by vessels stimulated in these 
cases is not the result of using only a single factor, but instead due to the transient nature of 
their presence. The short lifetime of proteins and their rapid transport out of tissues can 
results in only a short-term stimulus. A single protein delivered in a controlled manner may 
be able to provide enough signal to prolong the vascularization response and, possibly, 
increase vessel maturation. A number of delivery systems, including natural and synthetic 
biomaterials, have been developed for growth factor delivery. Commonly used materials 
include naturally occurring materials, such as alginate, gelatin and fibrin, as well as 
synthetic materials, such as poly (lactic-co-glycolic acid) (PLGA), and modified polyethylene 
glycol (PEG). Sustained growth factor delivery can be achieved and controlled using those 
materials in the form of hydrogels, micro/nano particles, fibers, porous matrix, or their 
combinations. (Chen & Mooney, 2003; Zisch et al., 2003a) The materials can be used to 
modulate delivery via diffusive resistance or through direct interactions between the 
materials and the growth factors. For example, the release of FGF-1 encapsulated in alginate 
microbeads can be modulated based on alginate composition. The release of FGF-1 from this 
relatively simple biomaterial can result in significantly prolonged increase in vascular 
density compared to a bolus injection of FGF-1. The enhancement in neovascularization can 
persist for greater than 6 weeks. In addition, release of FGF-1 from alginate can lead to a 
greater number of capillaries interacting with MCs but the fraction of MCs was not changed. 
(Moya et al., 2009, 2010) 
In addition to diffusion-controlled release, molecules can also be covalently immobilized to 
a polymeric surface or matrix for growth factor delivery and presentation. For example, 
VEGF has been covalently bound to fibrin gels resulting in cell demanded release. The 
immobilized VEGF cannot diffuse out and is only released as the fibrin is degraded. 
Compared to VEGF that diffuses from the fibrin gels, which formed leaky and chaotic 
vessels, the VEGF immobilized fibrin gels were able to stimulate the formation of nonleaky, 
organized vasculature with MC coverage and BM deposition. (Ehrbar et al., 2004) Synthetic 
polymer matrixes have also been used for immobilized growth factor delivery. PEG 
hydrogels modified with MMP sensitive degradation sequences and cell adhesion sequences 
have been used in combination with a number of growth factors, including VEGF (Leslie-
Barbick et al., 2011; Moon et al., 2010; Zisch et al., 2003b), Ephrin-A1 (Moon et al., 2007), and 
PDGF-BB (Saik et al., 2011). Capillary-like structures were formed only in the contact area 
with the immobilized VEGF in vitro, while after in vivo implantation, functional vessels were 
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formed with MC coverage. (Moon et al., 2010) Compared to single dose delivery, the 
sustained delivery of growth factors allows a more precise spatial control over the 
formation of vascular networks and may be able to lead to a more persistent vascular 
response and mature vessel formation even in the absence of additional maturation 
factors. 
3.1.2 Multiple factors delivery 
Since the formation of a stable vascular network appears to require the collaboration of a 
number of growth factors, the delivery of a combination (cocktail) of angiogenic molecules 
has been investigated as a method for improved vascular maturation. For example, co-
delivery of both FGF-2 and VEGF from an accellular collagen-heparin scaffold resulted in 
higher vessel density and more MC covered mature vessels, compared to single factor 
delivery. (Nillesen et al., 2007) In addition, some of the molecules involved in the 
angiogenesis stabilization signaling pathways (Table 1) have been delivered to the target 
tissue together with stimuli involved in the initiation step. PDGF-BB, a signaling protein 
stimulating MC proliferation and recruitment, has been used in combined delivery with 
VEGF (Chen et al., 2007; Richardson et al., 2001) and FGF-2 (Cao et al., 2003; Lu et al., 2007). 
Tested in many animal models, the dual delivery of PDGF-BB, a vessel maturation factor, 
with VEGF or FGF-2 resulted in not only an increase in vessel quantity, but also improved 
vessel quality. In a mouse corneal micropocket model, the dual delivery of PDGF-BB with 
FGF-2 led to stable vessels lasting for more than a year, while vessels formed by single 
delivery of PDGF-BB or FGF-2 regressed within 70 days (Cao et al., 2003). Other vessel 
maturation factors, such as Ang-1 (Peirce et al., 2003) and S1P (Tengood et al., 2010), have 
also been investigated in combined delivery systems with VEGF resulting in stable, long-
lasting vessels compared to VEGF delivery alone.  
Moreover, it appears that in dual factor delivery, the sequence of the molecules 
administrated matters. Angiogenic factors, such as VEGF and FGF, are involved in the 
initial stages of angiogenesis primarily acting on ECs, while vessel maturation factors, such 
as PDGF-BB, Ang-1 and S1P, are involved in the later stage of vessel stabilization, mostly 
targeting MCs. Therefore, a temporal separation for distinct kinetics is likely preferred with 
initial administration of angiogenic factor(s) followed by a vessel maturation factor(s). The 
sequential delivery of VEGF followed by S1P (Tengood et al., 2010) and FGF-2 followed by 
PDGF (Tengood et al., 2011) resulted in increased vessel density and stability compared to 
simultaneous dual delivery. A reverse in the sequential delivery results in decreased vessel 
density and stability, presumably due the factors working against each other. It was 
proposed that early delivery of vessel maturation factors restricts EC tube formation and 
expansion, resulting in decreased vessel density and vessel diameter. The late delivery of 
angiogenic factors was thought to then inhibit MC recruitment, resulting in excessive 
formation of immature vessels susceptible to regression. (Tengood et al., 2010, 2011)  
With certain modifications, sequential delivery of multiple growth factors can be achieved 
with delivery materials. For example, alginate can be made into multilayer microbeads with 
an internal region for slow protein release and external layer for faster protein release. 
(Khanna et al., 2010) PLGA, a biodegradable copolymer, can be made into microspheres 
encapsulated porous matrix, in which the microspheres are loaded with factor required for 
later stage of angiogenesis (PDGF-BB) with slow release kinetics, while the porous matrix is 
loaded with factor required for initial stage of angiogenesis (VEGF) with fast release rate. 
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(Carmeliet & Conway 2001; Richardson et al., 2001) Although the temporal and spatial 
kinetics of the growth factor(s) delivered to the target tissues can be controlled using certain 
delivery systems, there are still limitations existing with this strategy. The production and 
purification of massive amounts of active protein factors can be very expensive. And since 
most growth factors have relatively short half-lives, their bioactivity can be compromised 
due to storage, delivery routes, and metabolism in vivo. Moreover, the optimal combination 
and concentration of growth factors for different engineered tissues and the any side effect 
after long-term administration still need to be identified. 
3.2 Gene delivery 
3.2.1 Genes 
While the use of protein delivery offers improved control of the dose for the growth factors, 
there are also some disadvantages for those strategies, including expensive mass production 
of the proteins, and short protein half lives in vivo. Those limitations can potentially be 
overcome by means of gene therapy. (Rissanen et al., 2001) Gene therapy allows prolonged 
overexpression of proteins, theoretically leading to sustained therapeutic effects after a 
single application, with minor change in systemic growth factor concentrations. (Gosh et al., 
2008) Therefore, DNA sequences encoding for growth factors involved in angiogenesis can 
be used to improve neovascularization. In this section, we will only review genes used 
directly to the testing model or patients, either by systemic or local injection, or release from 
polymeric system. Genetic modification to cells for neovascularization will be introduced in 
the following section, cell therapies.   
Transient vegf gene expression in vivo results in potent angiogenic sprouting, however, the 
resulting vasculature appears to be immature and leaky, similar to the results of VEGF 
protein delivery. (Rissanen et al., 2003) When vegf gene is co-administrated with genes 
encoding angiogenic maturation factors, such as pdgf-b (Hao et al., 2004a; Korpisalo et al., 
2008; Kupatt et al., 2010) and ang-1 (Chen et al., 2007; Siddiqui et al., 2003; Su et al., 2009), the 
vasculature is longer-lasting and less permeable,with increased perfusion, which is also 
similar to the results of dual protein growth factor delivery. Other genes delivered for stable 
vascular networks formation includes ang-1 (Shyu et al., 1998), pdgf-b (Shea et al., 1999), fgf-2 
with pdgf-b (de Paula et al., 2009; Hao et al., 2004b), inf-β (Dickson et al., 2007), and neutrophin-
3 (Cristofaro et al., 2010).  
3.2.2 Vectors 
Vectors are needed in order for the genetic material to be transferred into cells and 
expressed. Commonly used vectors for gene delivery are plasmids and viral vectors. 
(Rissanen et al., 2001) Plasmids are DNA sequences that can automatically repeat and 
express in a host cells. They are easy to manufacture in a large quantity, and have low 
toxicity with a low immune response. However, naked plasmid DNA usually has very low 
transfection efficiency except in muscle tissue, therefore biomaterials have been used to 
increase plasmid-based gene transfer efficiency. (Yia-Herttuala & Alitalo, 2003) For example, 
PLGA, a degradable copolymer that has been widely used as a tissue engineering scaffold 
and drug delivery vehicle, has been applied as a carrier for plasmid. PLGA can be made into 
nanoparticles with the modification of cationic polymer chitosan to increase plasmid 
transfer efficiency. (Tahara et al., 2008) It can also be prepared as a matrix for sustained 
plasmid delivery, which in turn, results in longer term growth factor expression. (Nie et al., 
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2008) Viral vectors, on the other hand, have much higher transfection efficiency compared to 
naked plasmids, but have significant safety concerns. Adenoviruses (Levanon et al. 2006) 
and adeno-associated viruses (AAV) (Arsic et al., 2003) are the most commonly used viral 
vectors for growth factor gene delivery. While adenoviral vectors may cause inflammatory 
reactions and lack sustained expression, AAV only causes a very mild immune response 
and has shown long-term transgene expression, which makes it more attractive in gene 
therapy. (Dickson et al., 2007)  
Despite the success of gene therapies for the formation of stable vasculature in some animal 
models, clinical efficacy has yet to be observed. The pharmacokinetics and 
pharmacodynamics of gene vectors and products remain largely unknown and difficult to 
control. In addition, data from long-term follow up of clinical studies is lacking. (Yia-
Herttuala & Alitalo, 2003) Moreover, the method of gene delivery must be carefully selected 
to balance the need for maximum transfer efficiency with minimum risk of vector related 
safety issues. (Brey & McIntire, 2008) 
3.3 Cell therapies 
Although the delivery of growth factors or their genes has shown great potential to activate 
the host angiogenic response, certain pathological conditions may also require the 
transplantation of appropriate blood vessel forming cells, due to loss of, or damage to, the 
host vascular cells. In addition, these cells may rapidly assemble into vessels which can 
inosculate with the host, decreasing the time required for tissue perfusion relative to 
protein/gene approaches. In cell therapies, the cells would have to be isolated from donor 
or host sources, expanded and implanted into the target tissue, where the cells proliferate 
and incorporate into functional vessels. (Ennett & Mooney, 2002) ECs are of great interest in 
this strategy for their potentials to mimic vasculogenesis and assemble into capillary 
structures, as well as to release multiple angiogenic factors following implantation. (Brey et 
al., 2005, 2008) Transplantation of mature ECs have been shown to increase 
neovascularization in engineered tissues. (Nor et al., 2001) However, the limited availability 
and proliferation capability of mature ECs limtis this approach. (Kim & von Recum, 2008) 
Therefore, a number of other cell types and modifications may be needed in addition to the 
used of mature ECs for stable vasculature formation.  
Recent preclinical studies have shown that stem and progenitor cells derived from embryos 
or adult bone marrows have the potential to restore tissue vascularization after ischemic 
events. (Rafi & Lyden, 2003) Unlike mature cells, stem and progenitor cells have the 
potential to self-renew and differentiate into multiple cell types. While mature ECs seeded 
into collagen-fibronectin gels and implanted into different animal models suffered from 
poor perfusion and fast regression (Au et al., 2008b; Koike et al., 2004), ECs derived from 
human embryonic stem (hES) cells formed durable and functional blood vessels in vivo, 
supporting perfusion for over 150 days. (Wang et al., 2007) Co-delivery of ECs with 
mesenchymal stem cells (MSC) can also result in stable and functional vessels, lasting for 
more than 130 days, which was not achieved when either of the cell types were used alone. 
(Au et al., 2008a) 
Endothelial progenitor cells (EPCs) derived from circulating blood or bone marrow have 
also been used to introduce neovascularization in vivo. (Park et al., 2004) However, in order 
to form stable and durable vascular network, EPCs are often co-implanted with other cell 
types, such as VSMCs (Melero-Martin et al., 2007) or mesenchymal progenitor cells (MPCs) 
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(Melero-Martin et al., 2008). EPCs are expected to form the lumen of new vessels and 
VSMCs/MPCs serve as perivascular cells adjacent to the lumen providing survival and 
stability signals. EPCs derived from adult peripheral blood (PB) as well as umbilical cord 
blood (CB) have been compared for their ability to form functional long-lasting vessels in 
vivo. When co-implanted with 10T1/2 cells, a type of mouse MPCs, PB-EPCs and CB-EPCs 
both formed new vessels. While PB-EPCs formed vessels were unstable and regressed in 3 
weeks, CB-EPCs formed normal-functioning vessels that lasted for more than 4 months, 
possibly due to a greater proliferative capacity of these cells. (Au et al., 2008b) Therefore, CB-
EPCs hold great potential for their ability to form stable vasculature in engineered and 
regenerated tissues. Adipose-derived stromal cells (ASCs) have also been investigated as 
another potent candidate for neovascularization cell therapy, due to their ability to stimulate 
angiogenesis as well as vessel maturation in vivo. (Rubina et al., 2009) 
Cell therapies can also be used in combination with single or multiple growth factors or 
their genes to improve the function of the transplanted cells. Stromal cell derived factor-1 
(SDF-1), a small chemokine involved in recruiting EPCs, was delivered in combination with 
EPCs to promote EPC engraftement in ischemic muscle. (Kuliszewski et al., 2011; Yu et al., 
2009) Dual delivery of VEGF and MCP-1 from alginate microbeads has been shown to 
support EC transplantation, with VEGF improving survival of transplanted ECs and MCP-1 
inducing MCs recruitment. (Jay et al., 2010) A similar effect was observed when co-
delivering FGF-2 and granulocyte-colony stimulating factor (G-CSF) with bone marrow 
cells transplanted in a rodent model of critical limb ischemia. While FGF-2 directs EC 
migration and proliferation, G-CSF promotes the homing of bone marrow stem cells (in 
particular EPCs) to the ischemic site. (Layman et al., 2011) PLGA microparticles loaded 
with VEGF and hepatocyte growth factor (HGF), as well as Ang-1, were delivered in 
combination with cord blood derived vasculogenic progenitor cells. The delivery of triple 
growth factors significantly enhanced the effect of cell therapy in multiple animal models, 
with increased progenitor cell incorporation, improved vessel function, and stabilization. 
(Saif et al., 2010)  
In addition to combined gene or protein delivery with cells, ECs and EPCs can also be 
genetically modified ex vivo prior to implantation to enhance vascular stabilization. For 
example, Bcl-2 is an anti-apoptosis protein that is upregulated during angiogenesis. ECs 
transfected with the bcl-2 gene to inhibit EC apoptosis have shown increased vascular 
density and stability. Vessels formed with bcl-2 transduced ECs connect with host 
circulation and last for at least 2 months. (Enis et al., 2005; Schechner et al., 2000; Shepherd et 
al., 2009) EPCs with vegf gene overexpression have been shown to increase EPC migration 
and reduce serum starvation-induced apoptosis in vitro. (Yu et al., 2009) When implanted in 
vivo, the vegf transfected EPCs stimulated greater blood flow and angiogenesis in animal 
models of ischemia than EPCs alone. (Ikeda et al., 2004)  
In spite of the promising results seen with cell therapies, certain limitations still exist. First, 
the sources of cells for transplantation, either mature cells or progenitor cells, can be 
problematic. If autologous cells have to be used, there are usually limited number of cells 
available, not to mention that their viability and activity are compromised due to disease or 
aging of the patient. (Brey & McIntire, 2008) If allogeneic and xenogeneic cells can be used, 
they would initiate a host immune response, which requires immunosupressive medication, 
making the patient vulnerable to infection and other diseases. Secondly, the expansion of 
isolated cells ex vivo can be costly, time-consuming and technically challenging. If mature 
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ECs and VSMCs are used for transplantation, it often requires longer times to reach a 
sufficient number, due to their low self-renewal capability. Stem and progenitor cells, on 
the other hand, have much higher proliferation rate. However, the expansion of these cells 
while maintaining their multipotency may be a technical challenge. (Ennett & Mooney, 
2002) In addition, determination of the optimal cell types and concentration, delivery 
route, as well as identifying growth factors or genes to couple with cell transplantation 
requires further research. And lastly, the exact roles and ultimate fates of the transplanted 
cells remain largely unknown. Whether or not the transplanted cells would cause some 
other adverse complications, such as tumor angiogenesis, atheroma formation and 
retinopathies, is still unknown. (Rafii & Lyden, 2003) Those questions need to be 
answered with preclinical studies before proceeding to extensive clinical applications.  
3.4 Analytical methods 
3.4.1 In vitro models 
In order to investigate the efficacy of different tissue engineering strategies for 
neovascularization, a serial of preclinical tests should be done with different analytical 
models before jumping to any conclusion and proceeding with patients. In vitro models are 
usually used to allow the evaluation of a single or a combination of factors (protein, gene or 
cells) in a relatively simple, robust, and controlled system. Most early in vitro models of 
neovascularization only used ECs to spontaneous form tubes in a 2D or 3D environment to 
mimic angiogenesis or vasculogenesis. (Francis et al., 2008) Those models have been used to 
investigate the effect of soluble or insoluble factors, as well as genetic manipulation to the 
formation of new vessels in vitro. However, since the stabilization and remodeling stage of 
angiogenesis involves the interaction between ECs and MCs, many later studies have 
incorporated SMCs co-cultured with ECs. ECs and SMCs with a defined number can be co-
cultured as a spheroid and put into a 3D scaffold. By fluorescently labeling the two cell 
types with different dyes, the cells can be visualized and distinguished under fluorescence 
microscope. The coculture spheroid can spontaneously organize into a core of SMCs and a 
surface layer of ECs, which is a spherical mimic of cylindrical blood vessels where there is a 
surface of ECs and coating MCs. (Korff et al., 2001) This model allows study of the 
interactions between ECs and SMCs and their roles in angiogenesis and vessel stabilization. 
(Brey et al., 2005)  
Another in vitro model commonly used in studying angiogenesis and vessel stabilization is 
called aortic ring assay. (Nicosia & Ottinetti, 1990) The model results from the isolation of a 
1-2 mm cross-section of aorta from rats or mice which is then embedded in a 3D biomaterial. 
Under certain stimuli, new vessels form with an inner core of ECs and a outer layer of MCs, 
which can then be visualized by immunofluorescent staining for different cellular markers. 
By treating the culture with vessel maturation factors, such as Ang-1 and MCP-1, increased 
MC recruitment was observed in this model. (Aplin et al., 2010; Iurlaro et al., 2003) However, 
since the model uses an organ part with multiple cell types, many other undefined cell types 
can also contribute to the network formation. It is difficult to isolate the contribution of each 
cell type in this model. (Brey et al., 2005) 
3.4.2 In vivo models 
While the in vitro models provide convenient evaluation methods for the study of vessel 
assembly, the controlled environment differs dramatically from the actual in vivo 
www.intechopen.com
 
Formation of Stable Vascular Networks in Engineered Tissues 
 
491 
environment where other factors, such as blood flow, inflammatory response, endocrine 
regulation, etc. contribute to the process. Therefore, studies with in vitro models are often 
followed by in vivo studies. A number of in vivo models have been developed to isolate the 
process of neovascularization, with different aspects of focus in different organ systems. 
Commonly evaluated parameters in most in vivo models include: vessel density, SMC 
coverage rate, vessel lasting or regression time, vessel size distribution, blood perfusion rate, 
vessel permeability, etc.  
Subcutaneous implantation of scaffold materials is a commonly used method to evaluate 
protein, gene or cell therapies. (Jay et al., 2010; Shea et al., 1999; Tengood et al., 2010) Growth 
factors, genes or cells can be embedded a matrix material, which will then be implanted 
subcutaneously to animals as a "plug". The presence of therapeutic agents will affect local 
neovascularization and tissue invasion into the material. At different time points after the 
implantation, local tissues will be harvested for evaluation. Typically histologic analysis of 
vessel density, diameter, and SMC coverage are performed, but more sophisticated 
techniques such as confocal microscopy, vascular casts, and microCT following contrast 
enhancement can be used to provide a better understanding of vascular structure. This 
model is relatively easy to use, and can be applied to evaluate different therapeutic 
strategies. However, all animals need to be sacrificed in order for the neovascularization 
assessmment, and it only provides the evaluation of some basic parameters. Therefore, other 
animal models are often used to provide greater detail into the process.   
The mouse corneal micropocket assay allows for monitoring neovascularization without 
sacrificing animals. The method has been used by Cao et al. for the evaluation of vascular 
stability in response to dual growth factor delivery. Briefly, growth factor-loaded 
micropellets are implanted into a mouse corneal micropocket. Vessel lengths and 
vascularization areas of the eyes can be measured at various time points. The method allows 
the observation of neovascularization frequently without invasive surgery, thus limiting the 
number of animals used. Moreover, it allows long-term observation of vessel persistence. 
This method has only been used for evaluating growth factors or gene delivery, either as 
soluble factors (Cao et al., 2003; Lai et al., 2001; Lu et al., 2007) or immobilized in a hydrogel 
(Moon et al., 2010; Saik et al., 2010). Use of this model to evaluate cell therapies is still rare to 
our knowledge. On the other hand, cranial windows model of severe combined 
immunodeficient (SCID) mouse has been used to evaluate cell therapies. (Au et al., 
2008a,b; Wang et al., 2007) Similar to the corneal model, the cranial windows model also 
allows observation of neovascularization for several months without sacrificing the 
animals.  
Mice, rats or rabbits hindlimb ischemia models have been used to evaluate the efficacy of 
protein delivery, gene therapy and cell therapy in neovascularization. (Cao et al., 2003; de 
Paula et al., 2009; Laymen et al., 2011) The model applies ligation to the femoral artery and 
its branches to create ischemia in one limb. This model attempts to mimic peripheral arterial 
occlusive disease (PAOD), however this model only recreates the ischemic event and not the 
chronic vascular disease that lead to the condition in humans. After a certain treatment 
strategy, a number of neovascularizaiton parameters can be assessed, including flow 
recovery rate. The intensity of blood perfusion in the created ischemic area can be 
measured with different imaging techniques include laser Doppler or after systemically 
injection of fluorescent- or radio-labeled particles. Another ischemic model is the 
myocardial infraction heart model. Instead of femoral artery, the left anterior descend 
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artery (LAD) is ligated in the animal to create ischmia. (Hao et al., 2004) Besides common 
neovascularation parameters, cardiac morphology and function can also be evaluated 
using this model.  
There are also a number of other animal models used in evaluating angiogenesis and 
vascular stability. The chorioallantoic membrane (CAM) model with chicken or quail 
embryos is a simple method to evaluate vascularization in response to different therapies. 
(Saif et al., 2010; Stratman et al., 2010) After therapeutic agents injection or implantation, the 
angiogenic effect can be easily assessed by imaging vascular regions of the CAM. This 
model is cost efficient and easy to perform compared to other mammalian animal models. 
Suitable animal models should be selected based on the target function of the therapeutic 
strategy. In most cases, one single animal model may not be sufficient to testing all the 
aspects of interest in neovascularization, therefore multiple in vivo models may be required 
to provide extensive understanding of the potential strategy. In addition, if the technique is 
ultimately prepared for a specific tissue engineering application then the appropriate pre-
clinical model of the diseased or damaged tissue should be used.  
4. Conclusions  
The formation of stable vascular networks is critical for the survival of regenerated tissue in 
tissue engineering applications. In many cases, current strategies can result in immature 
vessel formation, providing poor perfusion and eventually leading to vessel regression. 
Recent studies have focused more on the later stage of neovascularization, which is the 
stabilization and remodeling of new vasculature. The process is highly regulated by both 
soluble and insoluble factors. Studies in the cellular and molecular mechanisms involved in 
vascular maturation have provided insight towards the development of strategies for the 
formation of stable vascular networks in engineered tissues. Successes have seen in many 
preclinical studies with these strategies; however, future success requires collaboration 
from interdisciplinary fields, including molecular and cellular biology, engineering and 
medicine.  
5. References 
Adams RH, Wilkinson GA, Weiss C, Diella F, Gale NW, Deutsch U, Risau W & Klein R. 
(1999). Roles of ephrinB ligands and EphB receptors in cardiovascular 
development: demarcation of arterial/venous domains, vascular morphogenesis, 
and sprouting angiogenesis. Genes Dev. Vol.13, No. 3, (February 1999), pp.295-306, 
ISSN 0890-9369 
Allende ML, Yamashita T & Proia RL. (2003) G-protein-coupled receptor S1P1 acts within 
endothelial cells to regulate vascular maturation. Blood. Vol.102, No.10, (November 
2003), pp. 3665-3667, ISSN 0006-4971  
Aplin AC, Fogel E, & Nicosia RF. (2010). MCP-1 promotes mural cell recruitment during 
angiogenesis in the aortic ring model. Angiogenesis, Vol. 13, No. 3, (September 
2010), pp. 219-226. ISSN 0969-6970  
Armulik A, Abramsson A & Betsholtz C. (2005) Endothelial/pericyte interactions.Circ Res. 
Vol.97, No.6, (September. 2005), pp.512-523. ISSN 0009-7300  
www.intechopen.com
 
Formation of Stable Vascular Networks in Engineered Tissues 
 
493 
Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, Kearne M, Magner M & 
Isner JM. (1999) Bone marrow origin of endothelial progenitor cells responsible for 
postnatal vasculogenesis in physiological and pathological neovascularization. Circ 
Res. Vol.85, No.3, (August 1999), pp.221-228. ISSN 0009-7300  
Arsic N, Zentilin L, Zacchigna S, Santoro D, Stanta G, Salvi A, Sinagra G & Giacca M. (2003) 
Induction of functional neovascularization by combined VEGF and angiopoietin-1 
gene transfer using AAV vectors. Mol Ther. Vol.7, No.4, (April 2003), pp.450-459. 
ISSN 1525-0016  
Au P, Tam J, Fukumura D & Jain RK. (2008a) Bone marrow-derived mesenchymal stem cells 
facilitate engineering of long-lasting functional vasculature. Blood. Vol.111, No.9, 
(May 2008), pp.4551-4558. ISSN 0006-4971  
Au P, Daheron LM, Duda DG, Cohen KS, Tyrrell JA, Lanning RM, Fukumura D, Scadden 
DT & Jain RK. (2008b) Differential in vivo potential of endothelial progenitor cells 
from human umbilical cord blood and adult peripheral blood to form functional 
long-lasting vessels. Blood. Vol.111, No.3, (February 2008), pp.1302-1305. ISSN 0006-
4971  
Benjamin LE & Keshet E. (1997) Conditional switching of vascular endothelial growth factor 
(VEGF) expression in tumors: induction of endothelial cell shedding and regression 
of hemangioblastoma-like vessels by VEGF withdrawal. Proc Natl Acad Sci U S A. 
Vol.94, No.16, (August 1997), pp.8761-8766. ISSN 0027-8424 
Benjamin LE, Hemo I, & Keshet E. (1998) A plasticity window for blood vessel remodelling 
is defined by pericyte coverage of the preformed endothelial network and is 
regulated by PDGF-B and VEGF. Development. Vol.125, No.9, (May 1998), pp.1591-
1598. ISSN 1011-6370  
Benjamin LE, Golijanin D, Itin A, Pode D, & Keshet E. (1999) Selective ablation of immature 
blood vessels in established human tumors follows vascular endothelial growth 
factor withdrawal.J Clin Invest. Vol.103, No.2, (January 1999), pp.159-165. ISSN 
0021-9738  
Brey EM, McIntire LV, Johnston CM, Reece GP & Patrick CW Jr. (2004) Three-dimensional, 
quantitative analysis of desmin and smooth muscle alpha actin expression during 
angiogenesis. Ann Biomed Eng. Vol.32, No.8, (August 2004), pp.1100-1107. ISSN 
0090-6964  
Brey EM, Uriel S, Greisler HP & McIntire LV. (2005) Therapeutic neovascularization: 
contributions from bioengineering. Tissue Eng. Vol.11, No,3-4, (March-April 2005), 
pp.567-584. ISSN 1937-3368  
Brey, E.M.; & McIntire, L.V. (2008). Vascular assembly in engineered and nature tissues, In: 
Principles of Regenerative Medicine, A. Atala,(Ed.), pp.1020-1037, Elsiver, ISBN 978-0-
12-369410-2, Burlington, MA, USA.  
Bussolino F, Mantovani A & Persico G. (1997) Molecular mechanisms of blood vessel 
formation. Trends Biochem Sci. Vol.22, No.7, ( July 1997), pp.251-256. ISSN 0968-
0004  
Cao R, Bråkenhielm E, Pawliuk R, Wariaro D, Post MJ, Wahlberg E, Leboulch P & Cao Y. 
(2003) Angiogenic synergism, vascular stability and improvement of hind-limb 
ischemia by a combination of PDGF-BB and FGF-2. Nat Med. Vol.9, No.5, (May 
2003), pp.604-613. ISSN 1078-8956  
www.intechopen.com
  
Regenerative Medicine and Tissue Engineering - Cells and Biomaterials 
 
494 
Cao Y, Hong A, Schulten H & Post MJ. (2005) Update on therapeutic neovascularization. 
Cardiovasc Res. Vol.65, No.3, (February 2005), pp.639-648. ISSN 2151-920X 
Carmeliet P. (2000) Mechanisms of angiogenesis and arteriogenesis. Nat Med. Vol.6, No.4, 
(April 2000), pp.389-395. ISSN 1078-8956  
Carmeliet P & Conway EM. (2001) Growing better blood vessels. Nat Biotechnol. Vol.19, 
No.11, (November 2001), pp.1019-1020. ISSN 1087-0156  
Carmeliet P. (2003) Angiogenesis in health and disease. Nat Med. Vol.9, No.6, (June 2003), 
pp.653-660. ISSN 1078-8956  
Chen F, Tan Z, Dong CY, Chen X & Guo SF. (2007) Adeno-associated virus vectors 
simultaneously encoding VEGF and angiopoietin-1 enhances neovascularization in 
ischemic rabbit hind-limbs. Acta Pharmacol Sin. Vol.28, No.4, (April 2007), pp.493-
502. ISSN 1671-4083  
Chen RR & Mooney DJ. (2003) Polymeric growth factor delivery strategies for tissue 
engineering. Pharm Res. Vol.20, No.8, (August 2003), pp.1103-1112. ISSN 0724-8741  
Chen RR, Silva EA, Yuen WW & Mooney DJ. (2007) Spatio-temporal VEGF and PDGF 
delivery patterns blood vessel formation and maturation. Pharm Res. Vol.24, No.2, 
(February 2007), pp.258-264. ISSN 0724-8741 
Cristofaro B & Emanueli C. (2009) Possible novel targets for therapeutic angiogenesis. Curr 
Opin Pharmacol. ; Vol.9, No.2, (April  2009), pp.102-108. ISSN 1471-4892  
Cristofaro B, Stone OA, Caporali A, Dawbarn D, Ieronimakis N, Reyes M, Madeddu P, Bates 
DO & Emanueli C. (2010) Neurotrophin-3 is a novel angiogenic factor capable of 
therapeutic neovascularization in a mouse model of limb ischemia. Arterioscler 
Thromb Vasc Biol. Vol.30, No.6, (June 2010), pp.1143-1150. ISSN 1079-5642  
Darland DC & D'Amore PA. (1999) Blood vessel maturation: vascular development comes 
of age. J Clin Invest. Vol.103, No.2, ( January 1999), pp.157-158. ISSN 0021-9738  
Davis GE & Senger DR. (2005) Endothelial extracellular matrix: biosynthesis, remodeling, 
and functions during vascular morphogenesis and neovessel stabilization.Circ Res.   
Vol.97, No.11, (November 2005), pp.1093-1107. ISSN 0009-7300  
Dejana E. (2004) Endothelial cell-cell junctions: happy together. Nat Rev Mol Cell Biol. Vol.5, 
No.4, (April 2004), pp.261-270. ISSN 1471-0072  
Dellian M, Witwer BP, Salehi HA, Yuan F & Jain RK. (1996) Quantitation and 
physiological characterization of angiogenic vessels in mice: effect of basic 
fibroblast growth factor, vascular endothelial growth factor/vascular 
permeability factor, and host microenvironment. Am J Pathol.Vol.149, No.1, ( July 
1996), pp.59-71. ISSN 0002-9440  
de Paula EV, Flores-Nascimento MC, Arruda VR, Garcia RA, Ramos CD, Guillaumon AT & 
Annichino-Bizzacchi JM. (2009) Dual gene transfer of fibroblast growth factor-2 and 
platelet derived growth factor-BB using plasmid deoxyribonucleic acid promotes 
effective angiogenesis and arteriogenesis in a rodent model of hindlimb ischemia. 
Transl Res. Vol.153, No.5, (May 2009), pp.232-239. ISSN 1943-8141  
Dimmeler S & Zeiher AM. (2000) Endothelial cell apoptosis in angiogenesis and vessel 
regression. Circ Res. Vol.87, No.6, (September 2000), pp.434-439. ISSN 0009-7300  
Donovan MJ, Lin MI, Wiegn P, Ringstedt T, Kraemer R, Hahn R, Wang S, Ibañez CF, Rafii S 
& Hempstead BL. (2000) Brain derived neurotrophic factor is an endothelial cell 
www.intechopen.com
 
Formation of Stable Vascular Networks in Engineered Tissues 
 
495 
survival factor required for intramyocardial vessel stabilization. Development. 
Vol.127, No.21, (November 2000), pp.4531-4540. ISSN 1011-6370  
Ehrbar M, Djonov VG, Schnell C, Tschanz SA, Martiny-Baron G, Schenk U, Wood J, Burri 
PH, Hubbell JA & Zisch AH. (2004) Cell-demanded liberation of VEGF121 from 
fibrin implants induces local and controlled blood vessel growth. Circ Res. Vol.94, 
No.8, (April 2004), pp.1124-1132. ISSN 0009-7300 
Enis DR, Shepherd BR, Wang Y, Qasim A, Shanahan CM, Weissberg PL, Kashgarian M, 
Pober JS & Schechner JS. (2005) Induction, differentiation, and remodeling of blood 
vessels after transplantation of Bcl-2-transduced endothelial cells. Proc Natl Acad Sci 
U S A. Vol.102, No.2, ( January 2005), pp.425-430. ISSN 0027-8424  
Ennett AB & Mooney DJ. (2002) Tissue engineering strategies for in vivo neovascularisation. 
Expert Opin Biol Ther. Vol.2, No.8, ( December 2002), pp.805-818. ISSN 1471-2598  
Francis ME, Uriel S & Brey EM. (2008) Endothelial cell-matrix interactions in 
neovascularization. Tissue Eng Part B Rev. Vol.14, No.1, (March 2008), pp.19-32. 
ISSN 1937-3368   
Francis-Sedlak ME, Moya ML, Huang JJ, Lucas SA, Chandrasekharan N, Larson JC, Cheng 
MH & Brey EM. (2010) Collagen glycation alters neovascularization in vitro and in 
vivo. Microvasc Res. Vol.80, No.1, (July 2010), pp.3-9. ISSN 0026-2862  
Gaengel K, Genové G, Armulik A & Betsholtz C. (2009) Endothelial-mural cell signaling in 
vascular development and angiogenesis. Arterioscler Thromb Vasc Biol. Vol.29, No.5, 
(May 2009), pp.630-638. ISSN 1079-5642  
Garmy-Susini B, Jin H, Zhu Y, Sung RJ, Hwang R & Varner J. (2005) Integrin alpha4beta1-
VCAM-1-mediated adhesion between endothelial and mural cells is required for 
blood vessel maturation.J Clin Invest. Vol.115, No.6, (June 2005), pp.1542-1551. ISSN 
0021-9738  
Gerhardt H & Betsholtz C. (2003) Endothelial-pericyte interactions in angiogenesis. Cell 
Tissue Res. Vol.314, No.1, (October 2003), pp.15-23. ISSN 0302-766X   
Ghajar CM, George SC & Putnam AJ. (2008) Matrix metalloproteinase control of capillary 
morphogenesis.Crit Rev Eukaryot Gene Expr.Vol.18,No.3,pp.251-278. ISSN 1045-
4403  
Ghosh R, Walsh SR, Tang TY, Noorani A & Hayes PD. (2008) Gene therapy as a novel 
therapeutic option in the treatment of peripheral vascular disease: systematic 
review and meta-analysis. Int J Clin Pract. Vol.62, No.9, (September 2008), pp.1383-
1390. ISSN 1368-5031  
Goumans MJ, Valdimarsdottir G, Itoh S, Rosendahl A, Sideras P & ten Dijke P. (2002) 
Balancing the activation state of the endothelium via two distinct TGF-beta type I 
receptors. EMBO J. Vol.21, No.7, (April 2002), pp.1743-1753. ISSN 0261-4189  
Greenberg JI, Shields DJ, Barillas SG, Acevedo LM, Murphy E, Huang J, Scheppke L, 
Stockmann C, Johnson RS, Angle N & Cheresh DA. (2008) A role for VEGF as a 
negative regulator of pericyte function and vessel maturation. Nature. Vol.456, 
No.7223, (December 2008), pp.809-813. ISSN 0028-0836  
Hao X, Månsson-Broberg A, Blomberg P, Dellgren G, Siddiqui AJ, Grinnemo KH, Wärdell E 
& Sylvén C. (2004a) Angiogenic and cardiac functional effects of dual gene transfer 
of VEGF-A165 and PDGF-BB after myocardial infarction.Biochem Biophys Res 
Commun. Vol.322, No.1, (September 2004), pp.292-296. ISSN 0006-291X  
www.intechopen.com
  
Regenerative Medicine and Tissue Engineering - Cells and Biomaterials 
 
496 
Hao X, Månsson-Broberg A, Gustafsson T, Grinnemo KH, Blomberg P, Siddiqui AJ, Wärdell 
E & Sylvén C. (2004b) Angiogenic effects of dual gene transfer of bFGF and PDGF-
BB after myocardial infarction. Biochem Biophys Res Commun. Vol.315, No.4, (March 
2004), pp.1058-1063. ISSN 0006-291X  
Hellberg C, Ostman A & Heldin CH. (2010) PDGF and vessel maturation. Recent Results 
Cancer Res. Vol.180, pp.103-114. ISSN 0080-0015  
Hellström M, Kalén M, Lindahl P, Abramsson A & Betsholtz C. (1999) Role of PDGF-B and 
PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during 
embryonic blood vessel formation in the mouse. Development. Vol.126, No.14, (June 
1999), pp.3047-3055. ISSN 1011-6370  
Iivanainen E, Nelimarkka L, Elenius V, Heikkinen SM, Junttila TT, Sihombing L, Sundvall 
M, Maatta JA, Laine VJ, Yla-Herttuala S, Higashiyama S, Alitalo K & Elenius K. 
(2003) Angiopoietin-regulated recruitment of vascular smooth muscle cells by 
endothelial-derived heparin binding EGF-like growth factor. FASEB J. Vol.17, 
No.12, (September 2003), pp.1609-1621. ISSN 0892-6638  
Ikeda Y, Fukuda N, Wada M, Matsumoto T, Satomi A, Yokoyama S, Saito S, Matsumoto K, 
Kanmatsuse K & Mugishima H. (2004) Development of angiogenic cell and gene 
therapy by transplantation of umbilical cord blood with vascular endothelial 
growth factor gene. Hypertens Res. Vol. 27, No.2, (February 2004), pp.119-28. ISSN 
0916-9636  
Iurlaro M, Scatena M, Zhu WH, Fogel E, Wieting SL & Nicosia RF. (2003) Rat aorta-derived 
mural precursor cells express the Tie2 receptor and respond directly to stimulation 
by angiopoietins.J Cell Sci. Vol. 116, No.17, (September 2003), pp.3635-3643. ISSN 
0021-9533  
Jain RK, Safabakhsh N, Sckell A, Chen Y, Jiang P, Benjamin L, Yuan F & Keshet E. (1998) 
Endothelial cell death, angiogenesis, and microvascular function after castration 
in an androgen-dependent tumor: role of vascular endothelial growth factor. Proc 
Natl Acad Sci U S A. Vol.95, No.18, (September 1998), pp.10820-10825. ISSN 0027-
8424  
Jain RK. (2003) Molecular regulation of vessel maturation. Nat Med. Vol. 9, No.6, (June 2003), 
pp.685-93. ISSN 1078-8956  
Jay SM, Shepherd BR, Andrejecsk JW, Kyriakides TR, Pober JS & Saltzman WM. (2010) Dual 
delivery of VEGF and MCP-1 to support endothelial cell transplantation for 
therapeutic vascularization. Biomaterials. Vol.31, No.11, (April 2010), pp.3054-3062. 
ISSN 0142-9612  
Kashiwagi S, Izumi Y, Gohongi T, Demou ZN, Xu L, Huang PL, Buerk DG, Munn LL, Jain 
RK & Fukumura D. (2005) NO mediates mural cell recruitment and vessel 
morphogenesis in murine melanomas and tissue-engineered blood vessels. J Clin 
Invest. Vol.115, No.7, (July 2005), pp.1816-1827. ISSN 0021-9738  
Khanna O, Moya ML, Greisler HP, Opara EC & Brey EM. (2010) Multilayered microcapsules 
for the sustained-release of angiogenic proteins from encapsulated cells. Am J Surg.  
Vol.200, No.5, (November 2010), pp.655-658. ISSN 0147-5185  
Kobayashi H, DeBusk LM, Babichev YO, Dumont DJ & Lin PC. (2006) Hepatocyte growth 
factor mediates angiopoietin-induced smooth muscle cell recruitment. Blood.   
Vol.108, No.4, (August 2006), pp.1260-1266. ISSN 0006-4971  
www.intechopen.com
 
Formation of Stable Vascular Networks in Engineered Tissues 
 
497 
Koike N, Fukumura D, Gralla O, Au P, Schechner JS & Jain RK. (2004) Tissue engineering: 
creation of long-lasting blood vessels. Nature. Vol.428, No.6979, (March 2004), 
pp.138-139. ISSN 0028-0836  
Korff T, Kimmina S, Martiny-Baron G & Augustin HG. (2001) Blood vessel maturation in a 
3-dimensional spheroidal coculture model: direct contact with smooth muscle cells 
regulates endothelial cell quiescence and abrogates VEGF responsiveness. FASEB J. 
Vol.15, No.2, ( February 2001), pp.447-457. ISSN 0892-6638  
Korpisalo P, Karvinen H, Rissanen TT, Kilpijoki J, Marjomäki V, Baluk P, McDonald DM, 
Cao Y, Eriksson U, Alitalo K & Ylä-Herttuala S. (2008) Vascular endothelial growth 
factor-A and platelet-derived growth factor-B combination gene therapy prolongs 
angiogenic effects via recruitment of interstitial mononuclear cells and paracrine 
effects rather than improved pericyte coverage of angiogenic vessels. Circ Res.   
Vol.103, No.10, (November 2008), pp.1092-1099. ISSN 0009-7300  
Kuliszewski MA, Kobulnik J, Lindner JR, Stewart DJ & Leong-Poi H. (2011) Vascular Gene 
Transfer of SDF-1 Promotes Endothelial Progenitor Cell Engraftment and 
Enhances Angiogenesis in Ischemic Muscle. Mol Ther. [ahead of print] ISSN 1525-
0016  
Kupatt C, Hinkel R, Pfosser A, El-Aouni C, Wuchrer A, Fritz A, Globisch F, Thormann M, 
Horstkotte J, Lebherz C, Thein E, Banfi A & Boekstegers P. (2010) Cotransfection of 
vascular endothelial growth factor-A and platelet-derived growth factor-B via 
recombinant adeno-associated virus resolves chronic ischemic malperfusion role of 
vessel maturation. J Am Coll Cardiol. Vol.56, No.5, (July 2010), pp.414-422. ISSN 
1558-3597  
Lai CM, Brankov M, Zaknich T, Lai YK, Shen WY, Constable IJ, Kovesdi I & Rakoczy PE. 
(2001) Inhibition of angiogenesis by adenovirus-mediated sFlt-1 expression in a rat 
model of corneal neovascularization. Hum Gene Ther. Vol.12, No.10, (July 2001), 
pp.1299-1310. ISSN 1043-0342  
Langer R & Vacanti JP. (1993) Tissue engineering. Science. Vol.260, No.5110, (May 1993), 
pp.920-926. ISSN 0036-8075  
Lawson ND, Scheer N, Pham VN, Kim CH, Chitnis AB, Campos-Ortega JA & Weinstein BM. 
(2001) Notch signaling is required for arterial-venous differentiation during 
embryonic vascular development. Development. Vol.128, No.19, (October 2001), 
pp.3675-3683. ISSN 1011-6370  
Layman H, Rahnemai-Azar AA, Pham SM, Tsechpenakis G & Andreopoulos FM. (2011) 
Synergistic angiogenic effect of codelivering fibroblast growth factor 2 and 
granulocyte-colony stimulating factor from fibrin scaffolds and bone marrow 
transplantation in critical limb ischemia. Tissue Eng Part A. Vol.17, No.1-2, ( January 
2011), pp.243-254. ISSN 1937-3368   
Leslie-Barbick JE, Shen C, Chen C & West JL. (2011) Micron-Scale Spatially Patterned, 
Covalently Immobilized Vascular Endothelial Growth Factor on Hydrogels 
Accelerates Endothelial Tubulogenesis and Increases Cellular Angiogenic 
Responses. Tissue Eng Part A.Vol.17, No.1-2, (January 2011), pp.221-229. ISSN 1937-
3368   
Letamendía A, Lastres P, Botella LM, Raab U, Langa C, Velasco B, Attisano L & Bernabeu C. 
(1998) Role of endoglin in cellular responses to transforming growth factor-beta. A 
www.intechopen.com
  
Regenerative Medicine and Tissue Engineering - Cells and Biomaterials 
 
498 
comparative study with betaglycan. J Biol Chem.Vol.273, No.49, (December 1998), 
pp.33011-33019. ISSN 0021-9258  
Levanon K, Varda-Bloom N, Greenberger S, Barshack I, Goldberg I, Orenstein A, Breitbart E, 
Shaish A & Harats D. (2006) Vascular wall maturation and prolonged angiogenic 
effect by endothelial-specific platelet-derived growth factor expression. 
Pathobiology. Vol.73, No.3, pp.149-158. ISSN 1015-2008  
Lindahl P, Johansson BR, Levéen P & Betsholtz C. (1997) Pericyte loss and microaneurysm 
formation in PDGF-B-deficient mice. Science. Vol.277, No.5323, (July 1997), pp.242-
245. ISSN 0036-8075  
Liu ZJ, Shirakawa T, Li Y, Soma A, Oka M, Dotto GP, Fairman RM, Velazquez OC & Herlyn 
M. (2003) Regulation of Notch1 and Dll4 by vascular endothelial growth factor in 
arterial endothelial cells: implications for modulating arteriogenesis and 
angiogenesis. Mol Cell Biol. Vol.23, No.1, (January 2003), pp.14-25. ISSN 0270-7306  
Lu H, Xu X, Zhang M, Cao R, Bråkenhielm E, Li C, Lin H, Yao G, Sun H, Qi L, Tang M, Dai 
H, Zhang Y, Su R, Bi Y, Zhang Y & Cao Y. (2007) Combinatorial protein therapy of 
angiogenic and arteriogenic factors remarkably improves collaterogenesis and 
cardiac function in pigs. Proc Natl Acad Sci U S A.Vol.104, No.29, (July 2007), 
pp.12140-12145. ISSN 0027-8424  
Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, Compton 
D, McClain J, Aldrich TH, Papadopoulos N, Daly TJ, Davis S, Sato TN & 
Yancopoulos GD. (1997) Angiopoietin-2, a natural antagonist for Tie2 that 
disrupts in vivo angiogenesis. Science. Vol. 77, No.5322, (July 1997), pp.55-60. 
ISSN 0036-8075  
Melero-Martin JM, Khan ZA, Picard A, Wu X, Paruchuri S & Bischoff J. (2007) In vivo 
vasculogenic potential of human blood-derived endothelial progenitor cells. Blood.   
Vol.109, No.11, (June 2007), pp.4761-4768. ISSN 0006-4971  
Melero-Martin JM, De Obaldia ME, Kang SY, Khan ZA, Yuan L, Oettgen P & Bischoff J. 
(2008) Engineering robust and functional vascular networks in vivo with human 
adult and cord blood-derived progenitor cells. Circ Res. Vol.103, No.2, (July 2008), 
pp.194-202. ISSN 0009-7300  
Mizugishi K, Yamashita T, Olivera A, Miller GF, Spiegel S & Proia RL. (2005) Essential role 
for sphingosine kinases in neural and vascular development. Mol Cell Biol. Vol.25, 
No.24, (December 2005), pp.11113-11121. ISSN 0270-7306  
Moon JJ, Lee SH & West JL. (2007) Synthetic biomimetic hydrogels incorporated with 
ephrin-A1 for therapeutic angiogenesis. Biomacromolecules. Vol.8, No.1, (January 
2007), pp.42-49. ISSN 1525-7797  
Moon JJ, Saik JE, Poché RA, Leslie-Barbick JE, Lee SH, Smith AA, Dickinson ME & West JL. 
(2010) Biomimetic hydrogels with pro-angiogenic properties. Biomaterials. Vol.31, 
No.14, (May 2010), pp.3840-3847. ISSN 0142-9612  
Moya ML, Lucas S, Francis-Sedlak M, Liu X, Garfinkel MR, Huang JJ, Cheng MH, Opara EC, 
& Brey EM. (2009) Sustained delivery of FGF-1 increases vascular density in 
comparison to bolus administration. Microvasc Res. Vol. 78, No.2, (September 2009), 
pp.142-147. ISSN 0026-2862. 
Moya ML, Garfinkel MR, Liu X, Lucas S, Opara EC, Greisler HP & Brey EM. (2010) 
Fibroblast growth factor-1 (FGF-1) loaded microbeads enhance local capillary 
www.intechopen.com
 
Formation of Stable Vascular Networks in Engineered Tissues 
 
499 
neovascularization.J Surg Res.Vol.160, No.2, (May 2010), pp.208-212. ISSN0022-
4804. 
Nie H, Lee LY, Tong H & Wang CH. (2008) PLGA/chitosan composites from a 
combination of spray drying and supercritical fluid foaming techniques: new 
carriers for DNA delivery. J Control Release. Vol.129, No.3, (August 2008), pp.207-
214. ISSN 0168-3659  
Nicosia RF & Ottinetti A (1990) Growth of microvessels in serumfree matrix culture of rat 
aorta. A quantitative assay of angiogenesis in vitro. Lab Invest. Vol.63, pp.115–122 
ISSN 0023-6837  
Nishishita T & Lin PC. (2004) Angiopoietin 1, PDGF-B, and TGF-beta gene regulation in 
endothelial cell and smooth muscle cell interaction. J Cell Biochem. Vol.91, No.3, 
(February 2004), pp.584-593. ISSN 0730-2312   
Nör JE, Christensen J, Mooney DJ & Polverini PJ. (1999) Vascular endothelial growth factor 
(VEGF)-mediated angiogenesis is associated with enhanced endothelial cell 
survival and induction of Bcl-2 expression. Am J Pathol.Vol.154, No.2, (February 
1999), pp.375-384. ISSN 0002-9440  
Nör JE, Peters MC, Christensen JB, Sutorik MM, Linn S, Khan MK, Addison CL, Mooney DJ 
& Polverini PJ. (2001) Engineering and characterization of functional human 
microvessels in immunodeficient mice. Lab Invest. Vol.81, No.4, (April 2001), 
pp.453-463. ISSN 0023-6837 
Paik JH, Skoura A, Chae SS, Cowan AE, Han DK, Proia RL & Hla T. (2004) Sphingosine 1-
phosphate receptor regulation of N-cadherin mediates vascular stabilization.Genes 
Dev. Vol.18, No.19, (October 2004), pp.2392-9403. ISSN 0890-9369  
Peirce SM, Price RJ & Skalak TC. (2004) Spatial and temporal control of angiogenesis and 
arterialization using focal applications of VEGF164 and Ang-1. Am J Physiol Heart 
Circ Physiol. Vol.286, No.3, (March 2004), pp.918-925. ISSN 0009-7300  
Pepper MS. (1997) Transforming growth factor-beta: vasculogenesis, angiogenesis, and 
vessel wall integrity.Cytokine Growth Factor Rev. Vol.8, No.1, (March 1997), pp.21-43. 
ISSN 1359-6101 
Rafii S & Lyden D. (2003) Therapeutic stem and progenitor cell transplantation for organ 
vascularization and regeneration. Nat Med. Vol.9, No.6, (June 2003), pp.702-712. 
ISSN 1078-8956  
Richardson TP, Peters MC, Ennett AB & Mooney DJ.(2001) Polymeric system for dual 
growth factor delivery. Nat Biotechnol. Vol.19, No.11, (November 2001), pp.1029-
1034. ISSN 1087-0156  
Rissanen TT, Vajanto I & Ylä-Herttuala S. (2001) Gene therapy for therapeutic angiogenesis 
in critically ischaemic lower limb - on the way to the clinic. Eur J Clin Invest.  Vol.31, 
No.8, (August 2001), pp.651-666. ISSN 0014-2972  
Rissanen TT, Markkanen JE, Gruchala M, Heikura T, Puranen A, Kettunen MI, Kholová I, 
Kauppinen RA, Achen MG, Stacker SA, Alitalo K & Ylä-Herttuala S. (2003) VEGF-D 
is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered 
into skeletal muscle via adenoviruses. Circ Res. Vol.92, No.10, (May 2003), pp.1098-
1106. ISSN 0009-7300  
Rubina K, Kalinina N, Efimenko A, Lopatina T, Melikhova V, Tsokolaeva Z, Sysoeva V, 
Tkachuk V & Parfyonova Y. (2009) Adipose stromal cells stimulate angiogenesis via 
www.intechopen.com
  
Regenerative Medicine and Tissue Engineering - Cells and Biomaterials 
 
500 
promoting progenitor cell differentiation, secretion of angiogenic factors, and 
enhancing vessel maturation.Tissue Eng Part A. Vol.15, No.8, (August 2009), 
pp.2039-2050. ISSN 1937-3368   
Saif J, Schwarz TM, Chau DY, Henstock J, Sami P, Leicht SF, Hermann PC, Alcala S, Mulero 
F, Shakesheff KM, Heeschen C & Aicher A. (2010) Combination of injectable 
multiple growth factor-releasing scaffolds and cell therapy as an advanced 
modality to enhance tissue neovascularization. Arterioscler Thromb Vasc Biol.  
Vol.30, No.10, (October 2010), pp.1897-1904. ISSN 1079-5642  
Saik JE, Gould DJ, Watkins EM, Dickinson ME & West JL.(2011) Covalently immobilized 
platelet-derived growth factor-BB promotes angiogenesis in biomimetic 
poly(ethylene glycol) hydrogels. Acta Biomater. Vol.7, No.1, (January 2011), pp.133-
143. ISSN 1742-7061  
Sato TN, Tozawa Y, Deutsch U, Wolburg-Buchholz K, Fujiwara Y, Gendron-Maguire M, 
Gridley T, Wolburg H, Risau W & Qin Y. (1995) Distinct roles of the receptor 
tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature. Vol.376, No.6535, 
(July 1995), pp.70-74. ISSN 0028-0836  
Schechner JS, Nath AK, Zheng L, Kluger MS, Hughes CC, Sierra-Honigmann MR, Lorber 
MI, Tellides G, Kashgarian M, Bothwell AL & Pober JS. (2000) In vivo formation of 
complex microvessels lined by human endothelial cells in an immunodeficient 
mouse. Proc Natl Acad Sci USA.Vol.97, No.16, (August 2000), pp.9191-9196. ISSN 
0027-8424  
Shea LD, Smiley E, Bonadio J & Mooney DJ. (1999) DNA delivery from polymer matrices 
for tissue engineering. Nat Biotechnol. Vol.17, No.6, (June 1999), pp .551-554. 
ISSN1087-0156  
Shepherd BR, Jay SM, Saltzman WM, Tellides G & Pober JS. (2009) Human aortic smooth 
muscle cells promote arteriole formation by coengrafted endothelial cells. Tissue 
Eng Part A. Vol.15, No.1, (January 2009), pp.165-173. ISSN 1937-3368   
Shyu KG, Manor O, Magner M, Yancopoulos GD & Isner JM. (1998) Direct intramuscular 
injection of plasmid DNA encoding angiopoietin-1 but not angiopoietin-2 
augments revascularization in the rabbit ischemic hindlimb. Circulation. Vol.98, 
No.19, (November 1998), pp.2081-2087. ISSN 0009-7322  
Siddiqui AJ, Blomberg P, Wärdell E, Hellgren I, Eskandarpour M, Islam KB & Sylvén C. 
(2003) Combination of angiopoietin-1 and vascular endothelial growth factor gene 
therapy enhances arteriogenesis in the ischemic myocardium. Biochem Biophys Res 
Commun. Vol.310, No.3, (October 2003), pp.1002-1009. ISSN 0006-291X  
Sneider EB, Nowicki PT & Messina LM. (2009) Regenerative medicine in the treatment of 
peripheral arterial disease. J Cell Biochem.Vol.108, No.4, (November 2009), pp.753-
761. ISSN 0730-2312  
Stratman AN, Malotte KM, Mahan RD, Davis MJ & Davis GE. (2009) Pericyte recruitment 
during vasculogenic tube assembly stimulates endothelial basement membrane 
matrix formation. Blood.Vol.114, No.24, (December 2009), pp.5091-5101. ISSN 0006-
4971  
Stratman AN, Schwindt AE, Malotte KM & Davis GE. (2010) Endothelial-derived PDGF-BB 
and HB-EGF coordinately regulate pericyte recruitment during vasculogenic tube 
www.intechopen.com
 
Formation of Stable Vascular Networks in Engineered Tissues 
 
501 
assembly and stabilization. Blood.Vol.116, No.22, (November 2010), pp.4720-4730. 
ISSN 0006-4971  
Su H, Takagawa J, Huang Y, Arakawa-Hoyt J, Pons J, Grossman W & Kan YW. (2009) 
Additive effect of AAV-mediated angiopoietin-1 and VEGF expression on the 
therapy of infarcted heart. Int J Cardiol. Vol.133, No.2, (April 2009), pp.191-197. 
ISSN 0167-5273  
Sullivan DC & Bicknell R. (2003) New molecular pathways in angiogenesis. Br J Cancer.   
Vol.89, No.2, (July 2003), pp.228-231. ISSN 0007-0920  
Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, Sato TN & Yancopoulos 
GD. (1996) Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during 
embryonic angiogenesis. Cell. Vol.87, No.7, (December 1996), pp.1171-1180.ISSN 
0092-8674  
Tahara K, Sakai T, Yamamoto H, Takeuchi H & Kawashima Y. (2008) Establishing chitosan 
coated PLGA nanosphere platform loaded with wide variety of nucleic acid by 
complexation with cationic compound for gene delivery. Int J Pharm. Vol.354, No.1-
2, (April 2008), pp.210-216. ISSN 0378-5173  
Tengood JE, Kovach KM, Vescovi PE, Russell AJ & Little SR. (2010) Sequential delivery of 
vascular endothelial growth factor and sphingosine 1-phosphate for angiogenesis. 
Biomaterials. Vol.31, No.30, (October 2010), pp.7805-7812. ISSN 0142-9612  
Tengood JE, Ridenour R, Brodsky R, Russell AJ & Little SR. (2011) Sequential Delivery of 
Basic Fibroblast Growth Factor and Platelet-Derived Growth Factor for 
Angiogenesis. Tissue Eng Part A. [ahead of print] ISSN 1937-3368   
Thurston G, Suri C, Smith K, McClain J, Sato TN, Yancopoulos GD & McDonald DM. (1999) 
Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-
1. Science. Vol.286, No.5449, (December 1999), pp.2511-2514. ISSN 0036-8075  
Thurston G, Rudge JS, Ioffe E, Zhou H, Ross L, Croll SD, Glazer N, Holash J, McDonald DM 
& Yancopoulos GD. (2000) Angiopoietin-1 protects the adult vasculature against 
plasma leakage. Nat Med. Vol.6, No.4, (April 2000), pp.460-463. ISSN 1078-8956  
Uutela M, Wirzenius M, Paavonen K, Rajantie I, He Y, Karpanen T, Lohela M, Wiig H, 
Salven P, Pajusola K, Eriksson U & Alitalo K. (2004) PDGF-D induces 
macrophage recruitment, increased interstitial pressure, and blood vessel 
maturation during angiogenesis. Blood.Vol.104, No.10, (November 2004), pp.3198-
3204. ISSN 0006-4971   
van den Driesche S, Mummery CL & Westermann CJ. (2003) Hereditary hemorrhagic 
telangiectasia: an update on transforming growth factor beta signaling in 
vasculogenesis and angiogenesis. Cardiovasc Res. Vol.58, No.1, (April 2003), pp.20-
31. ISSN 2151-920X.  
Wang HU, Chen ZF & Anderson DJ. (1998) Molecular distinction and angiogenic interaction 
between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-
B4. Cell. Vol.93, No.5, ( May 1998), pp.741-753. ISSN 0092-8674  
Wang ZZ, Au P, Chen T, Shao Y, Daheron LM, Bai H, Arzigian M, Fukumura D, Jain RK & 
Scadden DT. (2007) Endothelial cells derived from human embryonic stem cells 
form durable blood vessels in vivo. Nat Biotechnol. Vol.25, No.3, (March 2007), 
pp.317-318. ISSN 1087-0156  
www.intechopen.com
  
Regenerative Medicine and Tissue Engineering - Cells and Biomaterials 
 
502 
Ylä-Herttuala S & Alitalo K. (2003) Gene transfer as a tool to induce therapeutic vascular 
growth. Nat Med. Vol.9, No.6, ( June 2003), pp.694-701. ISSN 1078-8956  
Yu JX, Huang XF, Lv WM, Ye CS, Peng XZ, Zhang H, Xiao LB & Wang SM. (2009) 
Combination of stromal-derived factor-1alpha and vascular endothelial growth 
factor gene-modified endothelial progenitor cells is more effective for ischemic 
neovascularization. J Vasc Surg. Vol.50, No.3, (September 2009), pp.608-616. ISSN 
1078-5884  
Zisch AH, Lutolf MP & Hubbell JA. (2003a) Biopolymeric delivery matrices for angiogenic 
growth factors. Cardiovasc Pathol. Vol.12, No.6, (November-December 2003), pp.295-
310. ISSN 1054-8807  
Zisch AH, Lutolf MP, Ehrbar M, Raeber GP, Rizzi SC, Davies N, Schmökel H, Bezuidenhout 
D, Djonov V, Zilla P & Hubbell JA. (2003b) Cell-demanded release of VEGF from 
synthetic, biointeractive cell ingrowth matrices for vascularized tissue growth. 
FASEB J. Vol.17, No.15, (December 2003), pp.2260-2262. ISSN 0892-6638  
www.intechopen.com
Regenerative Medicine and Tissue Engineering - Cells and
Biomaterials
Edited by Prof. Daniel Eberli
ISBN 978-953-307-663-8
Hard cover, 588 pages
Publisher InTech
Published online 29, August, 2011
Published in print edition August, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Tissue Engineering may offer new treatment alternatives for organ replacement or repair deteriorated organs.
Among the clinical applications of Tissue Engineering are the production of artificial skin for burn patients,
tissue engineered trachea, cartilage for knee-replacement procedures, urinary bladder replacement, urethra
substitutes and cellular therapies for the treatment of urinary incontinence. The Tissue Engineering approach
has major advantages over traditional organ transplantation and circumvents the problem of organ shortage.
Tissues reconstructed from readily available biopsy material induce only minimal or no immunogenicity when
reimplanted in the patient. This book is aimed at anyone interested in the application of Tissue Engineering in
different organ systems. It offers insights into a wide variety of strategies applying the principles of Tissue
Engineering to tissue and organ regeneration.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Bin Jiang and Eric M. Brey (2011). Formation of Stable Vascular Networks in Engineered Tissues,
Regenerative Medicine and Tissue Engineering - Cells and Biomaterials, Prof. Daniel Eberli (Ed.), ISBN: 978-
953-307-663-8, InTech, Available from: http://www.intechopen.com/books/regenerative-medicine-and-tissue-
engineering-cells-and-biomaterials/formation-of-stable-vascular-networks-in-engineered-tissues
© 2011 The Author(s). Licensee IntechOpen. This chapter is distributed
under the terms of the Creative Commons Attribution-NonCommercial-
ShareAlike-3.0 License, which permits use, distribution and reproduction for
non-commercial purposes, provided the original is properly cited and
derivative works building on this content are distributed under the same
license.
